<p>根據公司在最近向證券交易委員會的披露，Evergreen Capital Management LLC 在第四季度減少了對禮來公司的持股，下降幅度為 8.6%。該基金在季度內出售了 968 股後，持有該公司 10,288 股股票。截至其最近向證券交易委員會的備案，Evergreen Capital Management LLC 在禮來公司的持股價值為 7,942,000 美元。</p>
<p>獲取 <strong>禮來公司</strong> 的提醒：</p>
<ul>
<li>目前哪個醫療保健股票是最佳購買？</li>
</ul>
<p>其他幾家機構投資者和對沖基金最近也對該公司的持股進行了調整。Highline Wealth Partners LLC 在第四季度將其在禮來公司的持股增加了 80.0%。Highline Wealth Partners LLC 現在擁有 45 股該公司的股票，價值 35,000 美元，此前在上個季度又購買了 20 股。FPC Investment Advisory Inc.在第四季度將其在禮來公司的持股增加了 358.3%。FPC Investment Advisory Inc.現在擁有 55 股該公司的股票，價值 45,000 美元，此前又購買了 43 股。Prudent Man Investment Management Inc.在第四季度購買了禮來公司的新頭寸，價值約 48,000 美元。Compass Financial Services Inc 在第四季度購買了禮來公司的新頭寸，價值約 50,000 美元。最後，Fiduciary Advisors Inc.在第四季度購買了禮來公司的新股份，價值約 58,000 美元。機構投資者持有該公司 82.53% 的股票。</p>
<h2>分析師評級上調與下調</h2>
<p>LLY 成為多份研究分析師報告的主題。高盛集團在 4 月 8 日的研究報告中將禮來公司的股票評級從 “中性” 上調至 “買入”，並將該公司的目標價從 892.00 美元下調至 888.00 美元。Leerink Partners 在 1 月 17 日的研究報告中為禮來公司設定了 950.00 美元的目標價。摩根士丹利在 4 月 9 日的報告中將禮來公司的目標價從 1,146.00 美元下調至 1,124.00 美元，併為該公司設定了 “增持” 評級。富國銀行在 3 月 5 日的報告中將禮來公司的目標價從 970.00 美元上調至 1,100.00 美元，並給予該公司 “增持” 評級。最後，StockNews.com 在 2 月 7 日的研究報告中將禮來公司的股票評級從 “持有” 上調至 “買入”。兩位股票研究分析師對該股票給予了持有評級，十八位分析師對該公司給予了買入評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，共識目標價為 1,012.00 美元。</p>
<ul>
<li>價格目標顯示這三隻股票接近 1 萬億美元的標誌</li>
</ul>
<p><strong>閲讀我們關於禮來公司的最新報告</strong></p>
<h2>禮來公司股票表現</h2>
<p>NYSE LLY 的股票在週三開盤價為 756.55 美元。該公司的市值為 7173.4 億美元，市盈率為 64.61，市盈增長比率為 1.40，貝塔值為 0.51。禮來公司的 52 周低點為 677.09 美元，52 周高點為 972.53 美元。該公司的債務與股本比率為 2.00，速動比率為 0.97，流動比率為 1.15。該公司的 50 日移動平均線為 832.96 美元，200 日移動平均線為 821.54 美元。</p>
<ul>
<li>AbbVie 股票通過進入減肥市場提升投資組合</li>
</ul>
<p>禮來公司（NYSE:LLY - 獲取免費報告）在 2 月 6 日星期四發佈了其財報。該公司報告季度每股收益為 5.32 美元，低於分析師一致預期的 5.45 美元，差額為 0.13 美元。禮來公司的股本回報率為 85.24%，淨利潤率為 23.51%。整體來看，分析師預計禮來公司在當前財政年度將發佈 23.48 美元的每股收益。</p>
<h2>內部人員買賣</h2>
<p>在相關消息中，首席會計官 Donald A. Zakrowski 於 3 月 13 日星期四出售了該公司 1,000 股股票。該股票以 818.24 美元的平均價格出售，總價值為 818,240.00 美元。出售完成後，首席會計官現在直接持有該公司 5,840 股股票，價值 4,778,521.60 美元。此次交易代表其持股減少了 14.62%。該出售在向證券交易委員會的備案中披露，相關信息可通過此鏈接獲取。公司內部人士目前持有 0.13% 的股票。</p>
<h2>禮來公司公司簡介</h2>
<p>（免費報告）</p>
<p>禮來公司在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素利普羅、胰島素利普羅原料、胰島素利普羅混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；以及 Zepbound 用於肥胖。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票比禮來公司更好</li>
<li>什麼是股息競爭者？投資股息競爭者</li>
<li>小心 BigBear.ai：內部人士正在出售——你應該怎麼辦？</li>
<li>什麼是股票市場指數，如何使用它們？</li>
<li>CrowdStrike 股票在網絡威脅環境擴展時是買入</li>
<li>每月股息股票的利弊</li>
<li>國會！在關税引發的崩潰中，誰交易了什麼</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在禮來公司嗎？</h2>
<p>在考慮禮來公司之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦在更廣泛的市場注意到之前購買……而禮來公司並不在名單上。</p>
<p>雖然禮來公司目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

禮來

<p>Evergreen Capital Management LLC 在第四季度減少了對禮來公司的持股，減持幅度為 8.6%，出售了 968 股，剩餘持股為 10,288 股，價值約為 794 萬美元。其他機構投資者也調整了他們的持倉，其中 Highline Wealth Partners LLC 和 FPC Investment Advisory Inc. 的增持尤為顯著。分析師們已上調了禮來股票的評級，普遍評級為 “適度買入”，目標價為 1,012.00 美元。該股票開盤價為 756.55 美元，市值為 7173.4 億美元，市盈率為 64.61</p>

<p>Evergreen Capital Management LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 8.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 10,288 shares of the company's stock after selling 968 shares during the quarter. Evergreen Capital Management LLC's holdings in Eli Lilly and Company were worth $7,942,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>根據公司在最近向證券交易委員會的披露，Evergreen Capital Management LLC 在第四季度減少了對禮來公司的持股，下降幅度為 8.6%。該基金在季度內出售了 968 股後，持有該公司 10,288 股股票。截至其最近向證券交易委員會的備案，Evergreen Capital Management LLC 在禮來公司的持股價值為 7,942,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>禮來公司</strong> 的提醒：</p>
</div><ul>
<li>Which Healthcare Stock Is the Best Buy Right Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>目前哪個醫療保健股票是最佳購買？</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently made changes to their positions in the company. Highline Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 80.0% in the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock worth $35,000 after purchasing an additional 20 shares in the last quarter. FPC Investment Advisory Inc. increased its holdings in Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after buying an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. purchased a new position in Eli Lilly and Company in the 4th quarter worth about $48,000. Compass Financial Services Inc bought a new position in Eli Lilly and Company during the 4th quarter valued at about $50,000. Finally, Fiduciary Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $58,000. Institutional investors own 82.53% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家機構投資者和對沖基金最近也對該公司的持股進行了調整。Highline Wealth Partners LLC 在第四季度將其在禮來公司的持股增加了 80.0%。Highline Wealth Partners LLC 現在擁有 45 股該公司的股票，價值 35,000 美元，此前在上個季度又購買了 20 股。FPC Investment Advisory Inc.在第四季度將其在禮來公司的持股增加了 358.3%。FPC Investment Advisory Inc.現在擁有 55 股該公司的股票，價值 45,000 美元，此前又購買了 43 股。Prudent Man Investment Management Inc.在第四季度購買了禮來公司的新頭寸，價值約 48,000 美元。Compass Financial Services Inc 在第四季度購買了禮來公司的新頭寸，價值約 50,000 美元。最後，Fiduciary Advisors Inc.在第四季度購買了禮來公司的新股份，價值約 58,000 美元。機構投資者持有該公司 82.53% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><p>LLY has been the topic of a number of research analyst reports. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and lowered their price objective for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a research note on Friday, January 17th. Morgan Stanley cut their price objective on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an &#34;overweight&#34; rating for the company in a report on Wednesday, April 9th. Wells Fargo &amp; Company increased their target price on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, March 5th. Finally, StockNews.com raised shares of Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Friday, February 7th. Two equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $1,012.00.</p>
<div class="lb-trans"><p>LLY 成為多份研究分析師報告的主題。高盛集團在 4 月 8 日的研究報告中將禮來公司的股票評級從 “中性” 上調至 “買入”，並將該公司的目標價從 892.00 美元下調至 888.00 美元。Leerink Partners 在 1 月 17 日的研究報告中為禮來公司設定了 950.00 美元的目標價。摩根士丹利在 4 月 9 日的報告中將禮來公司的目標價從 1,146.00 美元下調至 1,124.00 美元，併為該公司設定了 “增持” 評級。富國銀行在 3 月 5 日的報告中將禮來公司的目標價從 970.00 美元上調至 1,100.00 美元，並給予該公司 “增持” 評級。最後，StockNews.com 在 2 月 7 日的研究報告中將禮來公司的股票評級從 “持有” 上調至 “買入”。兩位股票研究分析師對該股票給予了持有評級，十八位分析師對該公司給予了買入評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，共識目標價為 1,012.00 美元。</p>
</div><ul>
<li>Price Targets Show These 3 Stocks Near the $1 Trillion Mark</li>
</ul>
<div class="lb-trans"><ul>
<li>價格目標顯示這三隻股票接近 1 萬億美元的標誌</li>
</ul>
</div><p><strong>Read Our Latest Report on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於禮來公司的最新報告</strong></p>
</div><h2>Eli Lilly and Company Stock Performance</h2>
<div class="lb-trans"><h2>禮來公司股票表現</h2>
</div><p>Shares of NYSE LLY opened at $756.55 on Wednesday. The company has a market cap of $717.34 billion, a P/E ratio of 64.61, a P/E/G ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The firm's fifty day moving average is $832.96 and its two-hundred day moving average is $821.54.</p>
<div class="lb-trans"><p>NYSE LLY 的股票在週三開盤價為 756.55 美元。該公司的市值為 7173.4 億美元，市盈率為 64.61，市盈增長比率為 1.40，貝塔值為 0.51。禮來公司的 52 周低點為 677.09 美元，52 周高點為 972.53 美元。該公司的債務與股本比率為 2.00，速動比率為 0.97，流動比率為 1.15。該公司的 50 日移動平均線為 832.96 美元，200 日移動平均線為 821.54 美元。</p>
</div><ul>
<li>AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market</li>
</ul>
<div class="lb-trans"><ul>
<li>AbbVie 股票通過進入減肥市場提升投資組合</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>禮來公司（NYSE:LLY - 獲取免費報告）在 2 月 6 日星期四發佈了其財報。該公司報告季度每股收益為 5.32 美元，低於分析師一致預期的 5.45 美元，差額為 0.13 美元。禮來公司的股本回報率為 85.24%，淨利潤率為 23.51%。整體來看，分析師預計禮來公司在當前財政年度將發佈 23.48 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人員買賣</h2>
</div><p>In related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. 0.13% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相關消息中，首席會計官 Donald A. Zakrowski 於 3 月 13 日星期四出售了該公司 1,000 股股票。該股票以 818.24 美元的平均價格出售，總價值為 818,240.00 美元。出售完成後，首席會計官現在直接持有該公司 5,840 股股票，價值 4,778,521.60 美元。此次交易代表其持股減少了 14.62%。該出售在向證券交易委員會的備案中披露，相關信息可通過此鏈接獲取。公司內部人士目前持有 0.13% 的股票。</p>
</div><h2>Eli Lilly and Company Company Profile</h2>
<div class="lb-trans"><h2>禮來公司公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>禮來公司在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素利普羅、胰島素利普羅原料、胰島素利普羅混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；以及 Zepbound 用於肥胖。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>What Are Dividend Contenders? Investing in Dividend Contenders</li>
<li>Beware of BigBear.ai: Insiders Are Selling—Should You?</li>
<li>What is a Stock Market Index and How Do You Use Them?</li>
<li>CrowdStrike Stock is a Buy as Cyberthreat Environment Expands</li>
<li>Pros And Cons Of Monthly Dividend Stocks</li>
<li>Congress! Who Traded What During the Tariff-Induced Meltdown</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票比禮來公司更好</li>
<li>什麼是股息競爭者？投資股息競爭者</li>
<li>小心 BigBear.ai：內部人士正在出售——你應該怎麼辦？</li>
<li>什麼是股票市場指數，如何使用它們？</li>
<li>CrowdStrike 股票在網絡威脅環境擴展時是買入</li>
<li>每月股息股票的利弊</li>
<li>國會！在關税引發的崩潰中，誰交易了什麼</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在禮來公司嗎？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮禮來公司之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦在更廣泛的市場注意到之前購買……而禮來公司並不在名單上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然禮來公司目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Evergreen Capital Management LLC 出售了禮來公司（NYSE:LLY）的 968 股股份